FDA Warns Clinics For Unlawful Advertising Of Allergan’s Lap-Band
This article was originally published in The Gray Sheet
Executive Summary
Billboards and advertising inserts promoted the Lap-Band procedure without providing adequate risk information, FDA charges.
You may also be interested in...
Apollo Endosurgery Wants Lap-Band To Become Even More Of An Asset
At the end of October, Apollo Endosurgery announced that it would acquire certain obesity assets from Allergan: Lap-Band, one of the most well-known brands in bariatric surgery, and Orbera, Allergan’s intra-gastric balloon system, the leading such product in Europe. It’s not unusual these days for large companies to unload under-performing businesses, but the Allergan deal is striking because of its choice of partner – Apollo Endosurgery is a small organization acquiring a much larger one.
Apollo Endosurgery Wants Lap-Band To Become Even More Of An Asset
At the end of October, Apollo Endosurgery announced that it would acquire certain obesity assets from Allergan: Lap-Band, one of the most well-known brands in bariatric surgery, and Orbera, Allergan’s intra-gastric balloon system, the leading such product in Europe. It’s not unusual these days for large companies to unload under-performing businesses, but the Allergan deal is striking because of its choice of partner. Apollo Endosurgery is a small organization acquiring a much larger one.
Allergan To Sell Lap-Band Franchise To Apollo For Up To $110 Million
The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.